Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $10.00 Average Target Price from Brokerages

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six ratings firms that are covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $10.00.

Several brokerages have recently weighed in on IRWD. Craig Hallum cut their price objective on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating for the company in a report on Wednesday. StockNews.com lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, November 12th.

Insider Activity

In related news, CFO Sravan Kumar Emany sold 11,001 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the sale, the chief financial officer now directly owns 309,572 shares of the company's stock, valued at approximately $1,263,053.76. This represents a 3.43 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several hedge funds have recently bought and sold shares of IRWD. KBC Group NV lifted its stake in Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 3,198 shares in the last quarter. Journey Strategic Wealth LLC acquired a new position in Ironwood Pharmaceuticals in the 4th quarter worth about $45,000. Wolverine Trading LLC acquired a new position in Ironwood Pharmaceuticals in the 3rd quarter worth about $51,000. Diversified Trust Co acquired a new position in Ironwood Pharmaceuticals in the 3rd quarter worth about $52,000. Finally, SG Americas Securities LLC acquired a new position in Ironwood Pharmaceuticals in the 4th quarter worth about $53,000.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ:IRWD traded down $0.06 on Friday, hitting $3.71. The company's stock had a trading volume of 1,010,590 shares, compared to its average volume of 1,573,422. Ironwood Pharmaceuticals has a 12 month low of $3.06 and a 12 month high of $15.70. The company has a market capitalization of $593.71 million, a price-to-earnings ratio of -123.67 and a beta of 0.34. The stock's 50-day moving average is $3.90 and its two-hundred day moving average is $4.56.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.07). The business had revenue of $91.60 million during the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company's revenue for the quarter was down 19.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.12 EPS. Equities analysts expect that Ironwood Pharmaceuticals will post 0.08 earnings per share for the current fiscal year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.